GlassScriptPhysician profile
Jose A Gonzalez
NPI 1184697732
$21,164.05
in general payments reported to CMS, 2019-2025
52 companies · $2,357 in 2025
The $2,357 reported for 2025 was more than what 97% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,848 · 2020: $3,496 · 2021: $3,140 · 2022: $2,468 · 2023: $2,819 · 2024: $2,036 · 2025: $2,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,066 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,065.64 |
| Education | $145.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,781.78 | 2019-2022 | |
| Abbvie INC. | $1,494.85 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,484.30 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,436.87 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,424.04 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $1,293.78 | 2019-2025 | Evenity, Otezla, Repatha |
| Glaxosmithkline, LLC. | $883.90 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $846.91 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $845.46 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $800.52 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $755.38 | 2019-2025 | Jardiance, Tradjenta |
| Sumitomo Pharma America, INC. | $677.61 | 2023-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $632.59 | 2019-2025 | |
| Pfizer INC. | $610.62 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $591.15 | 2019-2021 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $501.38 | 2019-2025 | Livalo, Zoryve, Seglentis |
| Mylan Specialty L.P. | $488.12 | 2019-2023 | Yupelri |
| Scilex Pharmaceuticals INC. | $472.03 | 2019-2023 | Ztlido |
| Radius Health, INC. | $462.04 | 2019-2021 | |
| Antares Pharma, INC. | $440.27 | 2021-2023 | Nocdurna, Xyosted, Tlando |
| Astellas Pharma US INC | $341.68 | 2019-2023 | Myrbetriq, Veozah |
| Otsuka America Pharmaceutical, INC. | $327.40 | 2023-2025 | Rexulti, Nuedexta |
| Allergan, INC. | $276.79 | 2019-2020 | |
| Corium, LLC | $269.36 | 2022-2024 | Adlarity, Azstarys |
| Merck Sharp & Dohme LLC | $256.59 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $212.96 | 2019-2023 | Xarelto |
| Biogen, INC. | $201.81 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $189.39 | 2022 | |
| Acadia Pharmaceuticals INC | $137.08 | 2019-2023 | Nuplazid |
| Halozyme INC | $99.63 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $88.56 | 2025 | |
| Esperion Therapeutics, INC. | $86.77 | 2020-2024 | Nexletol |
| Lundbeck LLC | $84.56 | 2025 | Rexulti |
| Abbott Laboratories | $81.60 | 2023-2025 | Freestyle Libre, Esprit |
| Ironwood Pharmaceuticals, INC | $73.76 | 2019-2023 | Linzess |
| Ardelyx, INC. | $64.51 | 2024 | Ibsrela |
| Eisai INC. | $61.51 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.71 | 2019-2021 | |
| Exact Sciences Corporation | $38.40 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $37.21 | 2019 | |
| Avanir Pharmaceuticals, INC. | $37.11 | 2019 | |
| Nabriva Therapeutics, Plc | $31.02 | 2020-2021 | |
| Edwards Lifesciences Corporation | $24.98 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.74 | 2025 | Caplyta |
| Smith+Nephew, INC. | $20.44 | 2021 | |
| Vivus LLC | $19.67 | 2021 | |
| Cmp Pharma, INC. | $19.20 | 2022 | |
| Nestle Healthcare Nutrition INC. | $17.01 | 2021 | |
| Genentech USA, INC. | $16.77 | 2019 | |
| Dermira, INC. | $16.72 | 2020 | |
| Neurocrine Biosciences, INC. | $14.97 | 2019 | |
| Ibsa Pharma INC. | $14.54 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.